Abstract: Embodiments described are generally directed to a method for applying a composition for managing dysallostasis effects to cannabinoids from repeated administration. The method envisions providing an anti-dysallostatic composition essentially comprised of a combination of phytoterpenoid and phytocannabinoid plus an independently derived phytoterpenoid that is between 70% and 95%, the phytocannabinoid includes THC and CBD. A dose of the composition is introduced to a subject sublingually while in a state of dysallostasis from prior consumption of the THC, the dose is approximately 5 mg of the THC, 1.25 mg of the CBD and 0.3-0.6 mg of the phytoterpenoid and between approximately 0.3-2.0 mg of the independently derived phytoterpenoid. The dose is increased if there is a change from the state of dysallostasis to two doses at a time interval, but if there is not a change from the state of dysallostasis, increasing administration of the composition sublingually to 3 doses at the predetermined interval.

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In certain embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol, cannabidiol and, optionally, terpenes such as linalool.

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.

Abstract: A cannabis plant extract based formulation to aid in stabilizing the therapeutic efficacy of cannabinoid containing treatments in patients affected with neurological diseases that comprises one or more of the following: Cannabidiol (CBD), tetrahydrocannabinol (THC), and terpenes; wherein the formulation comprises a high ratio of CBD to THC, with each of those cannabinoids in a relatively high concentration. The formulation also comprises Beta-caryophyllene that is used to further aid in neuroprotection by co-modulating CB1 and 2 receptors. Additionally, the formulation comprises the terpene humulene to assist in creating an “entourage effect” in conjunction with CBD, THC, and Beta-caryophyllene to stabilize and enhance treatment-related pharmacological actions. The formulation may also comprise Cannabichromene (CBC), Cannabigerol (CBG), and Cannabinol (CBN).

Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.